Technical Analysis for HEM - Hemostemix Inc.

Grade Last Price % Change Price Change
F 0.045 12.50% 0.005
HEM closed up 12.5 percent on Friday, April 26, 2024, on 70 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 13
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 12.50%
Shooting Star Candlestick Bearish 12.50%
180 Bearish Setup Bearish Swing Setup 12.50%
Expansion Breakdown Bearish Swing Setup 12.50%
Volume Surge Other 12.50%

   Recent Intraday Alerts

Alert Time
Up 1 ATR about 9 hours ago
Rose Above Lower Bollinger Band about 9 hours ago
Up 5% about 9 hours ago
Up 3% about 9 hours ago
Up 2% about 9 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Hemostemix Inc is a Canada-based clinical-stage biotechnology company. The Company's principal business is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions, including critical limb ischemia (CLI). The Company's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of CLI. ACP-01 is in a Phase II clinical trial in Canada, South Africa and the United States. The Company also focuses on developing other cell products, such as bone cell precursors (BCPs), myocardial cell precursors (MCPs) and neural cell precursors (NCPs). It operates in Canada and Israel. The Company has approximately 2,200 square foot research and manufacturing facility in Ness Ziona, Israel. Hemostemix Limited is the subsidiary of the Company.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Manufacturing Nature Clinic Biotechnology Biology Therapy Clinical Trial Bone Hypertension Stem Cells Cell Biology Cell Products Cell Therapy Manufacturing Facility

Is HEM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.175
52 Week Low 0.04
Average Volume 45,529
200-Day Moving Average 0.095
50-Day Moving Average 0.072
20-Day Moving Average 0.056
10-Day Moving Average 0.050
Average True Range 0.005
RSI (14) 32.89
ADX 27.09
+DI 20.752
-DI 42.105
Chandelier Exit (Long, 3 ATRs) 0.061
Chandelier Exit (Short, 3 ATRs) 0.054
Upper Bollinger Bands 0.070
Lower Bollinger Band 0.041
Percent B (%b) 0.14
BandWidth 52.252
MACD Line -0.007
MACD Signal Line -0.007
MACD Histogram -0.0008
Fundamentals Value
Market Cap 34.88 Million
Num Shares 775 Million
EPS -0.02
Price-to-Earnings (P/E) Ratio -2.14
Price-to-Sales 0.00
Price-to-Book 27.76
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.053
Resistance 3 (R3) 0.052 0.048 0.051
Resistance 2 (R2) 0.048 0.046 0.049 0.051
Resistance 1 (R1) 0.047 0.045 0.048 0.048 0.050
Pivot Point 0.043 0.043 0.044 0.044 0.043
Support 1 (S1) 0.042 0.041 0.043 0.043 0.040
Support 2 (S2) 0.038 0.040 0.039 0.039
Support 3 (S3) 0.037 0.038 0.039
Support 4 (S4) 0.038